Vyleesi is the first and only as-needed treatment approved by the Food and Drug Administration (FDA) for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD)
Roche will pay a purchase price of USD 295 million and an additional payment of up to USD 55 million
JB Chemicals will pay Rs 125 crore to Novartis to license the same drug portfolio for the Indian market
Employer-sponsored health insurance costs in India are expected to rise by 11% in 2024
A new GSK survey shows a large number of adults do not understand how shingles may be triggered
Total transaction value of the divestment is Rs. 3,660 million
India is following a holistic and inclusive approach in alignment with the vison of Universal Health Coverage and the resolute commitment to ‘leave no one behind
The initiative will focus on advocating for cleaner air
Three-point improvement achieved in Sex Ratio at Birth from 904 in 2017-19 to 907 in 2018-20
Subscribe To Our Newsletter & Stay Updated
